Jewell W R, Thomas J H, Sterchi J M, Morse P A, Humphrey L J
Ann Surg. 1976 May;183(5):543-9. doi: 10.1097/00000658-197605000-00011.
Over the past 8 years, 244 patients with Stage II or III melanoma have been treated by cutaneous injection of a crude acellular homogenate of allogeneic melanoma cells (V-I) or a more concentrated fraction (V-II), followed in most patients by exchanges of WBC between paired partners. Patients with Stage III disease exhibited an overall response rate of 24% and prolongation of survival compared with control data. Stage II patients also had prolonged survival and reduced rate of recurrence over historic peers' data. Breakdown of subgroup data revealed that V-II plus exchange of WBC is similar to V-I plus exchange or V-II alone. However, recent experience of LTF suggests a higher response rate than in either V-I or V-II groups, particularly when autochthonous tumor is used for cross-immunization. The most meaningful immunologic data resulted from analysis of DNCB and MIF data. Patients negative to DNCB rarely respond to immunotherapy. A positive pretreatment MIF or positive conversion following treatment correlates with response, whereas, conversion of positive to negative predicts poor clinical performance.
在过去8年中，244例II期或III期黑色素瘤患者接受了同种异体黑色素瘤细胞粗制无细胞匀浆（V-I）或更浓缩组分（V-II）的皮内注射治疗，大多数患者随后进行了配对伙伴之间的白细胞交换。与对照数据相比，III期疾病患者的总体缓解率为24%，生存期延长。II期患者的生存期也延长，且复发率低于历史同期患者的数据。亚组数据细分显示，V-II加白细胞交换与V-I加交换或单独使用V-II相似。然而，LTF最近的经验表明，其缓解率高于V-I或V-II组，特别是当使用自体肿瘤进行交叉免疫时。最有意义的免疫数据来自对DNCB和MIF数据的分析。对DNCB呈阴性的患者很少对免疫治疗有反应。治疗前MIF阳性或治疗后阳性转换与反应相关，而阳性转为阴性则预示临床疗效不佳。
